Clinical trials: Degenerative Neurologic Disease
Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis
Imaging Biomarkers in ALS
The purpose of the study is to determine if we are able to find one or more biomarkers of Amyotrophic Lateral Sclerosis (ALS) and Primary Lateral Sclerosis (PLS) using magnetic resonance imaging (MRI) scans at different levels, 3…
- Trial name
- NCT02567136
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Incomplete Spinal Cord Injury, Spasticity, Muscle
Activating Spinal Circuits to Improve Walking, Balance, Strength, and Reduce Spasticity
For many people with spinal cord injury (SCI), the goal of walking is a high priority. There are many approaches available to restore walking function after SCI; however, these approaches often involve extensive rehabilitation…
- Trial name
- NCT05429736
- Testing
- Motor Skill Training (MST), Transcutaneous Spinal Stimulation (TSS)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Shepherd Center, Atlanta GA
Parkinson
Clinical Investigation of NMS Assist
Parkinson's can cause a wide range of non-motor symptoms (NMS), including pain and problems with mental health, memory and sleep. These affect the quality of life of people with Parkinson's (PwP) and their care partners (CP).
- Trial name
- NCT05414071
- Testing
- NMS Assist
- Sponsor
- University of Plymouth
Alzheimer's Disease, Healthy
Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease
The purpose of this study is to assess the bioavailability of four experimental formulations relative to the current reference formulation used in the Phase 2 study.
- Trial name
- NCT00901498
- Testing
- BMS-708163
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Dravet Syndrome, Lennox Gastaut Syndrome
Intermediate-Size Expanded Access Protocol (EAP) for LP352
This is an intermediate-size expanded access program (EAP) study. The purpose of this EAP is to provide continued access to LP352, an investigational drug product being investigated in participants with DEEs.
- Conditions
- Dravet Syndrome, Lennox Gastaut Syndrome, Developmental and Epileptic Encephalopathies
- Trial name
- NCT06149663
- Testing
- LP352
- Where
- 22 sites in United States, Australia
- Sponsor
- Longboard Pharmaceuticals
Healthy Volunteers
A Study Assessing the Safety of Oral ATH-399A in Healthy Adult Participants
This study will evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of ATH-399A in healthy adults and also evaluate the effect of food on ATH-399A in order to develop mechanism-based and/or…
- Trial name
- NCT06088784
- Testing
- ATH-399A, ATH-399A 10 mg, 5 mg ATH-399A capsule
- Where
- Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- HanAll BioPharma Co., Ltd.
Asthma in Children, Allergy
Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing
The number and types of indoor air pollutants in schools is rising, however little is known about the impact of their potentially synergistic interactions, upon schoolchildren health.
- Trial name
- SynAIR-G (NCT05997784)
- Testing
- Performing lung function tests (spirometry and fraction of exhaled nitric oxide (FeNO)), Filling of standardized questionnaires, Using an App on a device
- Where
- France
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Parkinson's Disease, Dysarthria
A Comparison of Voice Amplifiers and Personal Communication Systems in Individuals With Parkinson's Disease
This study will compare two types of assistive devices for communication (a voice amplifier and a personal communication system) in individuals with a speech disorder related to Parkinson's disease.
- Trial name
- NCT02407067
- Testing
- ChatterVox, Easy Listener FM system (Phonic Ear Corp.)
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NF1, Neurofibromatosis
Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
This study, "A Phase II Study of Cabozantinib (XL l84) for Plexiform Neurofibromas in Subjects with Neurofibromatosis Type I in Children and Adults diagnosed with Neurofibromatosis Type 1 (NF1) and have a type of tumor called a…
- Conditions
- NF1, Neurofibromatosis, Plexiform Neurofibromas
- Trial name
- NF105-CABO (NCT02101736)
- Testing
- Cabozantinib
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Alabama at Birmingham
Alzheimer's Disease and Related Dementias
Reducing Behavioral and Psychological Symptoms of Dementia: Hospital Caregivers (Aim 2)
Persons with Alzheimer's Disease and Related Dementias (ADRD) account for 3.2 million hospital admissions per year and have over three times more hospitalizations than those without cognitive impairment, yet hospital caregivers…
- Trial name
- NCT04179721
- Testing
- PES-4-BPSD Model, The attention control condition
- Where
- 2 sites in United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Myotonic Dystrophy 1
Myotonic Dystrophy Type 1 Congenital and Juvenile Form: From Diagnosis to Rehabilitation [MDCJ-NeuBeRe]
The rationale of the study is to collect structured data in the neuropsychological, clinical neuroradiologic and neurorehabilitation fields in children/young people affected by congenital and juvenile myotonic dystrophy.
- Trial name
- MDCJ-NeuBeRe (NCT06378216)
- Testing
- neurocognitive evaluations
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS Eugenio Medea
Alzheimer Disease
Environmental Design for Behavioral Regulation in People With Dementia
Individuals with dementia present with changes in behaviors throughout the continuum of cognitive decline. Environmental features may be influential in behavioral regulation.
- Trial name
- NCT04555616
- Testing
- Standard Environmental Design, Individual Environmental Design
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Elizabeth K Rhodus
Huntington Disease, Alzheimer Disease
A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan
This drug-drug interaction study is being conducted to evaluate the potential effect of Dimebon on the pharmacokinetics on dextromethorphan, a probe substrate of the cytochrome P450 2D6 (CYP2D6) enzyme, after multiple dose…
- Trial name
- NCT00788047
- Testing
- Dextromethorphan, Dimebon + Dextromethorphan
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer Disease and Related Dementias (ADRD), Mild Cognitive Impairment (MCI)
Remote Sensing for ADRD-Specific Activities Identification in Older Adults
The investigators aim to use smart-home sensors and artificial intelligence (AI) to monitor and detect Alzheimer's Disease and Related Dementias (ADRD)-specific daily activities among older adults, with the goal of early symptom…
- Trial name
- NCT07120347
- Testing
- Remote Ambient Sensor System
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Alzheimer's Disease
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as…
- Trial name
- EMERGE (NCT02484547)
- Testing
- Aducanumab (BIIB037)
- Where
- 180 sites in United States, Belgium and 11 more
- Volunteers
- 1,643 people
- Sponsor
- Biogen
Tuberous Sclerosis Complex
Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants
The purpose of the study is to evaluate the efficacy, tolerability, and safety of vigabatrin versus rapamycin as a preventive treatment in infants with Tuberous Sclerosis Complex (TSC).
- Trial name
- ViRap (NCT04987463)
- Testing
- Vigabatrin, Rapamycin
- Where
- 2 sites in Poland
- Volunteers
- 60 people
- Sponsor
- Katarzyna Kotulska
Amyotrophic Lateral Sclerosis, Cerebrospinal Fluid
Compassionate Use of Ceftriaxone in Patients With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis is a uniformly progressive and fatal neurodegenerative disorder for which there is no known cure. In a novel attempt to widen the search for potential therapeutic agents, a NINDS- led cooperative…
- Conditions
- Amyotrophic Lateral Sclerosis, Cerebrospinal Fluid, Neurodegenerative Disease, Motor Neuron Disease
- Trial name
- NCT00718393
- Volunteers
- 1 people
- Sponsor
- Drexel University College of Medicine
PARKINSON DISEASE (Disorder)
Effect of Botulinum Toxin on Resting Tremor of the Refractory Upper Limb in Parkinsonians
Tremor is one of the most common symptoms in Parkinson Disease (PD), affecting almost 60% of patients. There is currently no specific treatment for tremor in PD, and 30% of patients develop drug-resistant tremor, making its…
- Trial name
- TOX PARK (NCT07822893)
- Where
- 2 sites in France
- Volunteers
- 39 people
- Sponsor
- University Hospital, Toulouse
Parkinson Disease, Freezing of Gait
Spinal Cord Stimulation for Gait Dysfunction in Parkinson's Disease
Parkinson's disease (PD) is the second commonest neurodegenerative disorder, affecting over 145,000 people in the UK. Initially, PD patients experience slowness of movements, limb stiffness, and tremor.
- Trial name
- SCORE-PD (NCT06005584)
- Testing
- Spinal Cord Stimulation - High Frequency SCS, Spinal Cord Stimulation - Burst SCS
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Imperial College London
Alzheimer Disease
Longitudinal Study Examining At-Home tDCS
Participants with dementia have reported improvements after receiving tDCS in a study at our lab. Although we make an effort to enroll such participants in further tDCS research studies, some participants are ineligible for…
- Trial name
- NCT04524338
- Testing
- Transcranial Direct Current Stimulation
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Lady Davis Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.